What to change when movement brings the ache back

What to change during the day

Divide a long household chore into shorter parts. Change position before the ache grows strong. If stairs hurt, use the rail and move one step at a time. Stop when the pain becomes sharp or sudden.

Try a shorter walk on flat ground. Rest before the joint begins throbbing. You don't need a painful test each day. The useful amount of movement leaves you no worse that evening.

What to try for simple relief

Heat can loosen a stiff joint before activity. Cold may feel better when movement brings swelling. Gentle exercise keeps the nearby muscles working. Stop and rest if soreness stays worse than it was before exercise.

When home care isn't enough, QC Kinetix can examine the joint. Its medical providers are the health care staff who check your movement and sore spots. They may offer regenerative treatments, meaning your blood is prepared at the clinic and placed at the sore area. The reason for offering this care is to seek easier movement without surgery.

They may call that joint preservation. In plain words, it means trying to keep your own joint working before choosing surgery. The visit can also cover alternatives to knee or hip surgery. Your exam will help decide whether those choices make sense.

When to stop testing the joint at home

Have the joint checked when soreness changes your sleep or walking. The exam may show whether the ache starts in the joint itself. For example, a lower back problem can send soreness toward the hip. That difference matters before you spend money on joint care.

Write down the tasks that you can't do now. Tell the provider what helped, even when relief was brief. Ask what comes next if the first treatment doesn't help. You won't need to agree until the answer is clear.

Sources

1. A meta-analysis of the PLACEBO arms of 73 double-blind trials (5,895 patients) quantified what a saline knee injection alone achieves: statistically and clinically significant improvement in pain, function and quality of life at 1, 3 and 6 months, with responder rates exceeding 50% at all three time points, peaking around 4-8 months and declining by 12 months. Placebo response was stronger in trials with more female participants and in more recently published trials.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression.. EFORT Open Reviews, 2025. DOI: 10.1530/EOR-2025-0022.

2. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. The BMJ meta-analysis of viscosupplementation pooled 169 trials (21,163 participants) and found clear evidence of small-study effects and publication bias. In the prespecified main analysis of 24 LARGE placebo-controlled trials (8,997 participants) hyaluronic acid reduced pain by SMD -0.08 (95% CI -0.15 to -0.02), equivalent to 2.0 mm on a 100 mm scale - far below the -0.37 minimal important difference - and trial sequential analysis showed there has been CONCLUSIVE evidence of clinical equivalence to placebo since 2009. Fifteen large trials showed a significantly higher risk of serious adverse events (RR 1.49).

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

4. The 2012 Annals of Internal Medicine meta-analysis of 89 viscosupplementation trials (12,667 adults) is the classic demonstration of publication bias in this field: the pooled effect across 71 trials was -0.37, but five UNPUBLISHED trials showed an effect size of -0.03, and 18 large trials with blinded outcome assessment showed a clinically irrelevant -0.11. Fourteen trials showed an increased risk of serious adverse events (RR 1.41).

   Rutjes AW, et al. — Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis.. Annals of Internal Medicine, 2012. DOI: 10.7326/0003-4819-157-3-201208070-00473.

5. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

6. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

7. A network meta-analysis of 11 RCTs (1,353 patients) with HIP osteoarthritis found that at 2-4 and 6 months NO intervention - corticosteroid, hyaluronic acid or PRP - significantly outperformed intra-articular saline placebo for either pain or function, while all interventions including placebo produced improvement exceeding the minimal clinically important difference from baseline. Evidence from the knee does not transfer to the hip.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.